Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported a 29% increase in net revenue for the quarter ended June 30, 2024. The company highlighted progress in its …
Harmony Biosciences Reports Q2 Growth and Expands Pipeline Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) recently denied a Citizen Petition filed by a short seller. The …
FDA Denies Petition Challenging Safety and Efficacy of Harmony Biosciences’ Drug Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets. The …
FDA Approves Harmony Biosciences’ WAKIX for Pediatric Narcolepsy Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) recently unveiled promising data at the annual meeting of the Associated Professional Sleep Societies, “SLEEP 2024.” The data from a Phase 2 …
Harmony Biosciences Presents Promising Data on Pitolisant for Myotonic Dystrophy Type 1 Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) announced its recent acquisition of Epygenix Therapeutics, Inc., marking a significant step into the rare epilepsy sector. This acquisition not only broadens …
Harmony Biosciences Expands into Rare Epilepsy Market with Epygenix Therapeutics Acquisition Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has released their Q1 2024 report indicating a 30% year-over-year growth in net revenue, sealing the quarter ending March 31, …
Rapidly Growing Harmony Biosciences Sees 30% Increase in Net Revenue, Boosts Growth Strategy With Rare Epilepsy Franchise Acquisition Read More